Reverse vaccinology-based multi-epitope COVID-19 vaccine targeting SARS-CoV-2 structural and non-structural proteins induces immune responses in mice
Vaccination is effective to end pandemics, including the Coronavirus disease-2019 (COVID-19). However, the evolution of Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) which is characterized by the emergence of the virus variants has a great potential to cause a decrease in the effectiv...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-06-01
|
| Series: | Vaccine: X |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590136225000269 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850226200864096256 |
|---|---|
| author | Azzania Fibriani Nicholas Yamahoki Annisa Meliana Shani Afifatur Rofiqoh Agust Leo Fany Siregar Cynthia Gunawan Carola Giovanni Danira Mayorga Tommy Octavianus Soetrisno Tjia Husna Nugrahapraja Ernawati Arifin Giri-Rachman Marselina Irasonia Tan |
| author_facet | Azzania Fibriani Nicholas Yamahoki Annisa Meliana Shani Afifatur Rofiqoh Agust Leo Fany Siregar Cynthia Gunawan Carola Giovanni Danira Mayorga Tommy Octavianus Soetrisno Tjia Husna Nugrahapraja Ernawati Arifin Giri-Rachman Marselina Irasonia Tan |
| author_sort | Azzania Fibriani |
| collection | DOAJ |
| description | Vaccination is effective to end pandemics, including the Coronavirus disease-2019 (COVID-19). However, the evolution of Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) which is characterized by the emergence of the virus variants has a great potential to cause a decrease in the effectiveness of the developed vaccines. One of the vaccine platforms that may overcome vaccine failure due to viral genetic mutations is a multi-epitope vaccine. Using the reverse vaccinology approach, in this study, we developed a multi-epitope peptide-based COVID-19 vaccine composed of immunodominant epitopes. The multi-epitope peptide was designed in silico, successfully expressed in E. coli BL21 (DE3), and purified. Furthermore, the vaccine candidate was proven to induce the production of SARS-CoV-2 antigen-specific IgM and IgG antibodies in BALB/c mice without any considerable adverse reaction. The results also showed that the generated antibodies were reactive to SARS-CoV-2-positive patient nasopharyngeal swab samples containing different circulating Omicron XBB F456L variants. Therefore, our study demonstrates that the multi-epitope peptide has the potential to be further developed as a safe and relevant COVID-19 vaccine. Additionally, this study also demonstrates that reverse vaccinology is useful to facilitate the development of relevant vaccines for emerging infectious diseases. |
| format | Article |
| id | doaj-art-03f5f90ef98245f19347f43d2a4eaad6 |
| institution | OA Journals |
| issn | 2590-1362 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Vaccine: X |
| spelling | doaj-art-03f5f90ef98245f19347f43d2a4eaad62025-08-20T02:05:08ZengElsevierVaccine: X2590-13622025-06-012410063210.1016/j.jvacx.2025.100632Reverse vaccinology-based multi-epitope COVID-19 vaccine targeting SARS-CoV-2 structural and non-structural proteins induces immune responses in miceAzzania Fibriani0Nicholas Yamahoki1Annisa Meliana Shani2Afifatur Rofiqoh3Agust Leo Fany Siregar4Cynthia Gunawan5Carola Giovanni Danira Mayorga6Tommy Octavianus Soetrisno Tjia7Husna Nugrahapraja8Ernawati Arifin Giri-Rachman9Marselina Irasonia Tan10School of Life Sciences and Technology, Institut Teknologi Bandung, Bandung, Indonesia; Corresponding author at: School of Life Sciences and Technology, Institut Teknologi Bandung, 10 Ganesa, Bandung 40132, Indonesia.School of Life Sciences and Technology, Institut Teknologi Bandung, Bandung, IndonesiaSchool of Life Sciences and Technology, Institut Teknologi Bandung, Bandung, IndonesiaSchool of Life Sciences and Technology, Institut Teknologi Bandung, Bandung, IndonesiaSchool of Life Sciences and Technology, Institut Teknologi Bandung, Bandung, IndonesiaSchool of Life Sciences and Technology, Institut Teknologi Bandung, Bandung, IndonesiaSchool of Life Sciences and Technology, Institut Teknologi Bandung, Bandung, IndonesiaSchool of Life Sciences and Technology, Institut Teknologi Bandung, Bandung, IndonesiaSchool of Life Sciences and Technology, Institut Teknologi Bandung, Bandung, IndonesiaSchool of Life Sciences and Technology, Institut Teknologi Bandung, Bandung, IndonesiaSchool of Life Sciences and Technology, Institut Teknologi Bandung, Bandung, IndonesiaVaccination is effective to end pandemics, including the Coronavirus disease-2019 (COVID-19). However, the evolution of Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) which is characterized by the emergence of the virus variants has a great potential to cause a decrease in the effectiveness of the developed vaccines. One of the vaccine platforms that may overcome vaccine failure due to viral genetic mutations is a multi-epitope vaccine. Using the reverse vaccinology approach, in this study, we developed a multi-epitope peptide-based COVID-19 vaccine composed of immunodominant epitopes. The multi-epitope peptide was designed in silico, successfully expressed in E. coli BL21 (DE3), and purified. Furthermore, the vaccine candidate was proven to induce the production of SARS-CoV-2 antigen-specific IgM and IgG antibodies in BALB/c mice without any considerable adverse reaction. The results also showed that the generated antibodies were reactive to SARS-CoV-2-positive patient nasopharyngeal swab samples containing different circulating Omicron XBB F456L variants. Therefore, our study demonstrates that the multi-epitope peptide has the potential to be further developed as a safe and relevant COVID-19 vaccine. Additionally, this study also demonstrates that reverse vaccinology is useful to facilitate the development of relevant vaccines for emerging infectious diseases.http://www.sciencedirect.com/science/article/pii/S2590136225000269SARS-CoV-2Recombinant vaccinePeptide-based vaccineMulti-epitope vaccineReverse vaccinologyImmunogenicity |
| spellingShingle | Azzania Fibriani Nicholas Yamahoki Annisa Meliana Shani Afifatur Rofiqoh Agust Leo Fany Siregar Cynthia Gunawan Carola Giovanni Danira Mayorga Tommy Octavianus Soetrisno Tjia Husna Nugrahapraja Ernawati Arifin Giri-Rachman Marselina Irasonia Tan Reverse vaccinology-based multi-epitope COVID-19 vaccine targeting SARS-CoV-2 structural and non-structural proteins induces immune responses in mice Vaccine: X SARS-CoV-2 Recombinant vaccine Peptide-based vaccine Multi-epitope vaccine Reverse vaccinology Immunogenicity |
| title | Reverse vaccinology-based multi-epitope COVID-19 vaccine targeting SARS-CoV-2 structural and non-structural proteins induces immune responses in mice |
| title_full | Reverse vaccinology-based multi-epitope COVID-19 vaccine targeting SARS-CoV-2 structural and non-structural proteins induces immune responses in mice |
| title_fullStr | Reverse vaccinology-based multi-epitope COVID-19 vaccine targeting SARS-CoV-2 structural and non-structural proteins induces immune responses in mice |
| title_full_unstemmed | Reverse vaccinology-based multi-epitope COVID-19 vaccine targeting SARS-CoV-2 structural and non-structural proteins induces immune responses in mice |
| title_short | Reverse vaccinology-based multi-epitope COVID-19 vaccine targeting SARS-CoV-2 structural and non-structural proteins induces immune responses in mice |
| title_sort | reverse vaccinology based multi epitope covid 19 vaccine targeting sars cov 2 structural and non structural proteins induces immune responses in mice |
| topic | SARS-CoV-2 Recombinant vaccine Peptide-based vaccine Multi-epitope vaccine Reverse vaccinology Immunogenicity |
| url | http://www.sciencedirect.com/science/article/pii/S2590136225000269 |
| work_keys_str_mv | AT azzaniafibriani reversevaccinologybasedmultiepitopecovid19vaccinetargetingsarscov2structuralandnonstructuralproteinsinducesimmuneresponsesinmice AT nicholasyamahoki reversevaccinologybasedmultiepitopecovid19vaccinetargetingsarscov2structuralandnonstructuralproteinsinducesimmuneresponsesinmice AT annisamelianashani reversevaccinologybasedmultiepitopecovid19vaccinetargetingsarscov2structuralandnonstructuralproteinsinducesimmuneresponsesinmice AT afifaturrofiqoh reversevaccinologybasedmultiepitopecovid19vaccinetargetingsarscov2structuralandnonstructuralproteinsinducesimmuneresponsesinmice AT agustleofanysiregar reversevaccinologybasedmultiepitopecovid19vaccinetargetingsarscov2structuralandnonstructuralproteinsinducesimmuneresponsesinmice AT cynthiagunawan reversevaccinologybasedmultiepitopecovid19vaccinetargetingsarscov2structuralandnonstructuralproteinsinducesimmuneresponsesinmice AT carolagiovannidaniramayorga reversevaccinologybasedmultiepitopecovid19vaccinetargetingsarscov2structuralandnonstructuralproteinsinducesimmuneresponsesinmice AT tommyoctavianussoetrisnotjia reversevaccinologybasedmultiepitopecovid19vaccinetargetingsarscov2structuralandnonstructuralproteinsinducesimmuneresponsesinmice AT husnanugrahapraja reversevaccinologybasedmultiepitopecovid19vaccinetargetingsarscov2structuralandnonstructuralproteinsinducesimmuneresponsesinmice AT ernawatiarifingirirachman reversevaccinologybasedmultiepitopecovid19vaccinetargetingsarscov2structuralandnonstructuralproteinsinducesimmuneresponsesinmice AT marselinairasoniatan reversevaccinologybasedmultiepitopecovid19vaccinetargetingsarscov2structuralandnonstructuralproteinsinducesimmuneresponsesinmice |